Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Consensus Price Target of $26.25

Protara Therapeutics, Inc. (NASDAQ:TARA) has been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $26.25.

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th.

Protara Therapeutics Price Performance

TARA stock traded up $0.09 during trading hours on Thursday, reaching $2.53. 728,221 shares of the stock were exchanged, compared to its average volume of 926,978. The firm’s 50-day moving average is $2.89 and its 200-day moving average is $4.39. The company has a market cap of $155.77 million, a price-to-earnings ratio of -1.82 and a beta of 1.54. Protara Therapeutics has a 12 month low of $2.09 and a 12 month high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. As a group, equities research analysts forecast that Protara Therapeutics will post -1.37 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP raised its stake in shares of Protara Therapeutics by 120.1% during the 3rd quarter. Marshall Wace LLP now owns 1,543,284 shares of the company’s stock worth $4,707,000 after purchasing an additional 842,263 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Protara Therapeutics by 86.7% in the 1st quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock valued at $4,824,000 after buying an additional 430,014 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Protara Therapeutics by 133.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after buying an additional 304,110 shares in the last quarter. Walleye Capital LLC grew its stake in shares of Protara Therapeutics by 204.0% in the first quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after buying an additional 297,525 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Protara Therapeutics during the second quarter worth $526,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.